Penn Center for Innovation

SERES Therapeutics, Inc.

Posted on May 12, 2016 — Kat Hinkel

PCI negotiated a multi-year collaboration with Seres Therapeutics, Inc. a leading microbiome therapeutics platform company to support the development of novel treatment approaches for certain rare genetic metabolic diseases including urea cycle disorders, and inflammatory bowel disease (IBD). Under the terms of the agreement, Penn Professors Gary D. Wu, M.D., and James Lewis, M.D., two global leaders in the field of the microbiome, plan to conduct investigator sponsored research evaluating rationally designed bacterial compositions for patients with ulcerative colitis.
Press Release

Category: